Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion

Circulation Journal

Volumn 71, Issue 1, 2007, Pages 46-51

  Komatsu, Takashi ^a   Tachibana, Hideaki ^a   Sato, Yoshihiro ^a   Ozawa, Mahito ^a   Nakamura, Motoyuki ^a   Okumura, Ken ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Amiodarone; Atrial fibrillation; Prevention; Remodeling

Indexed keywords

AMIODARONE; APRINDINE; BEPRIDIL; CIBENZOLINE; DISOPYRAMIDE; FLECAINIDE; PILSICAINIDE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LOADING DRUG DOSE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; RASH; RECURRENT DISEASE; SINUS RHYTHM; SYMPTOMATOLOGY;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846000688     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.46     Document Type: Article

References (30)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285: 2370-2375.
2. Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH. Pharmacological intervention in atrial fibrillation (PIAF) study investigators: Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation: Results from a prospective randomized study. Eur Heart J 2003; 24: 1430-1436.
3. Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med 1999; 341: 910-911.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-988.
5. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695-703.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly: The Framingham study. Arch Intern Med 1987; 147: 1561-1564.
7. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al for the STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1690-1696.
8. Komatsu T, Nakamura S, Suzuki O, Horiuchi D, Yomogida K, Okumura K. Long-term prognosis of the patients with paroxysmal atrial fibrillation depends on the response to antiarrhythmic therapy. Circ J 2004; 68: 729-733.
9. Komatsu T, Sato Y, Tachibana H, Nakamura T, Horiuchi D, Okumura K. A randomized crossover study on the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: Influence of the duration of arrhythmia before therapy. Circ J 2006; 70: 667-672.
10. Komatsu T, Nakamura S, Yomogida K, Kimura M, Owada S, Okumura K. Early defibrillation increases the subsequent log-term effect of cibenzoline in patients with symptomatic atrial fibrillation (abstract). Circ J 2002; 66(Suppl I): 346.
11. Komatsu T, Yomogida K, Nakamura S, Suzuki O, Horiuchi D, Kameda K, et al. Relationship between duration of arrhythmia and subsequent preventive effect of disopyramide after cardioversion in patients with symptomatic paroxysmal and persistent atrial fibrillation. J Cardiol 2003; 42: 111-117 (in Japanese with English abstract).
12. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM sub-study of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42: 30-32.
13. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus sotaolo for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
14. Nattel S, Li D. Ionic remodeling in the heart: Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000; 87: 440-447.
15. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al. Management of patients with atrial fibrillation. Circulation 1996; 93: 1262-1277.
16. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997; 35: 13-29.
17. Kodama I, Kamiya K, Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising Class III agent. Am J Cardiol 1999; 84: 20R-28R.
18. + current. Circulation 2001; 103: 1317-1324.
19. Uemura H, Ogura T, Reien Y, Kishimoto T, Ishikura H, Nakaya H. Inhibition of HCN4 channel current by amiodarone: A new approach for preventing ectopic activity from pulmonary veins. Eur J Pharamcol 2006 (in press).
20. Geotte A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: Time course and mechanisms. Circulation 1996; 94: 2968-2974.
21. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 81: 512-525.
22. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling of the atria. Circulation 1999; 100: 2191-2197.
23. Shinagawa K, Ahiroshita-Takeshita A, Schram G, Nattel S. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: Insights into the mechanism of superior efficacy of amiodarone. Circulation 2003; 107: 1440-1446.
24. Prichett ELC, DaTorre SD, Platt ML, McCarville SE, Hougham AJ, for the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate treatment of paroxysmal supraventricular and paroxysmal atrial fibrillation: Dose-response studies. J Am Coll Cardiol 1991; 17: 297-303.
25. Lau CP, Leung WH, Wong CK. A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992; 124: 645-650.
26. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557-1570.
27. UK Propafenone PSVT study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995; 92: 2550-2557.
28. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-227.
29. Fukuda Y, Akaishi M, Noma S, Mitamura H, Ogawa S. Asymptomatic recurrence of atrial fibrillation: Cardiophone-guided management (abstract). Circ J 2003; 67(Suppl): 310.
30. Allessie MA. Atrial electrophysiologic remodeling. J Cardiovasc Electrophysiol 1998; 9: 1378-1393.